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At mucosal sites, papillomavirus genomes can persist in the epithelial basal layer following immune-mediated regression. Subse-
quent T-cell depletion stimulates a 3- to 5-log increase in the viral copy number, to levels associated with productive infection.
Reappearance of microlesions was rare within the short time frame of our experiments but was observed in one instance. Our
studies provide direct evidence that immunosuppression can trigger the reactivation of latent papillomavirus genomes, as previ-
ously proposed in humans.
Definitive evidence of human papillomavirus (HPV) latencyhas been difficult to obtain, and for the most part has been
limited to anecdotal reports of recurrence in individuals. The
prevalence of HPV disease in immunosuppressed patients is
thought to result from the reactivation of latent infections (1–8),
and as reviewed by Gravitt, there is growing evidence that HPV
latency and the persistence of particular HPV types (even in the
absence of apparent disease) constitutes an important risk factor
in the development of cervical neoplasia (9, 10). The ability of
papillomaviruses to persist long-term in a latent state (i.e., in the
absence of disease) has been shown most convincingly in animal
models and has led to the suggestion that latencymay be a general
consequence of immune-mediated regression (11–14). The low-
titer inoculation of cottontail rabbit papillomavirus (CRPV) can
lead to an asymptomatic cutaneous infection that can be activated
by UV light to form lesions (14), and more recently, we have
shown that rabbit oral papillomavirus (ROPV) can persist for a
year ormore in infected oralmucosa following immune-mediated
regression of productive infection (12). In the ROPV study of
immune-mediated latency, viral genomes were found by laser
capture microscopy to be restricted to the epithelial basal layer at
the site of previous infection, without significant genome ampli-
fication or virion production in the differentiated cell layers (12).
In humans, the suppression of T-cell immunity, either by the ad-
ministration of drugs such as cyclosporine to renal transplant re-
cipients or following human immunodeficiency virus (HIV) in-
fection, has been proposed as a cause of latent HPV reactivation at
sites of previous disease (1–8).Waning T-cell immunity may sim-
ilarly explain the increased detection of HPV in older womenwho
lack signs of cervical disease by cytology. Because of the difficulties
of demonstrating papillomavirus reactivation in humans, we de-
cided instead to assess whether suppression of T-cell immunity in
latently ROPV-infected rabbits (i.e., where the site of previous
infection is known)might provide clearer evidence of reactivation
following immune-mediated regression and allow us to establish
whether immune changes can regulate the basal cell copy number
and the ability to detect infection, as has been suggested in hu-
mans.
Immunosuppression prevents spontaneous ROPV papil-
loma regression. Following experimental ROPV infection of the
lingual mucosa of immunocompetent rabbits, papillomas form
within 4 weeks and immune-mediated regression is complete by 8
weeks postinfection, with no evidence of lesion presence by 10
weeks (12). Spontaneous regression of papillomas is a universal
outcome of experimental ROPV infection, with the detection of
both viral DNA and RNA in the absence of apparent disease for at
least a year postinfection (12). The spontaneous reactivation of
ROPV to form a productive infection occurs very rarely in immu-
nocompetent animals, suggesting that latent viral genomes are
held in check by the host immune system (12). Interestingly, the
administration of the immunosuppressive drug cyclosporine to
domestic rabbits can prevent the regression of cutaneous CRPV
papillomas (15) and delay the regression of ROPVoral papillomas
(16). To examine this with a view to developing an immunosup-
pressive regimen suitable for reactivation studies, seven female
New Zealand White rabbits were infected with ROPV prepared
from rabbit warts with permanent marking of the infected sites
with tattoo ink as previously described (12). Concurrently, 15
mg/kg cyclosporine (Sandimmun; Sandoz Ltd., UnitedKingdom)
was administered by subcutaneous injection three times per week
to four of the rabbits. As expected, papillomas had regressed com-
pletely at 8 weeks postinfection in the control rabbits and by 9
weeks postinfection in the three cyclosporine-treated rabbits. In
our initial studies, therefore, we were able to delay papilloma re-
gression by only 7 days or so andwere unable to prevent regression
completely. Interestingly, although a slight reduction in CD8
cells was apparent after 8 weeks of cyclosporine treatment com-
pared to controls, there was no significant decrease in CD4 cells,
in accordance with the limited effect on the timing of regression
that was seen. All of the rabbits showed adverse side effects upon
cyclosporine treatment, including inappetence, lethargy, reduced
weight gain, and abscess formation at the injection sites, as has
previously been reported (17, 18), with one rabbit having to be
culled at 5 weeks postinfection because of weight loss and respira-
tory disease (severe pulmonary abscess formation). Our efforts to
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optimize the cyclosporine dosing schedule were confounded by
severe weight loss problems among the treated animals, which we
concluded would limit our capacity to initiate the long-term im-
munosuppression experiments required for reactivation studies.
To overcome these difficulties, we therefore decided to administer
a lower level of cyclosporine togetherwith the corticosteroid dexa-
methasone (which reduces CD4 and CD8 cell counts in rabbits),
in order to reduce adverse responses (19). Concurrent with the
experimental infection of four rabbits with ROPV, we initiated
triweekly administration of cyclosporine at 15 mg/kg and bi-
weekly administration of 0.5mg/kg dexamethasone (Dexadreson;
MSD Animal Health Ltd., United Kingdom) by subcutaneous in-
jection into three animals. In the infected control rabbit and in
one immunosuppressed rabbit, all papillomas had completely re-
gressed by 10 weeks postinfection, but in two immunosuppressed
rabbits, papillomaswere present and continued to growuntil drug
administration ceased at 15 weeks postinfection (Fig. 1A). Al-
though one rabbit was subsequently culled because of excessive
weight loss, the other retained papillomas until week 19 (i.e., 4
weeks after termination of immunosuppression) before regress-
ing. In both animals, papillomas appeared to grow laterally in all
directions, eventually coalescing to form large confluent lesions
on the tongue. Papillomas also appeared at sites that had not un-
dergone experimental infection, suggesting that immunosuppres-
FIG 1 (A) Presence of florid ROPV-induced warts in immunosuppressed rabbits at 15 weeks postinfection. In immunocompetent rabbits, lesions were not
detectable beyond 10 weeks. (B and C) In the immunosuppressed rabbits, secondary infections were also apparent at nonscarified sites by 15 weeks postinfection
(p.i.). (D) Lesion size and abundance varied among immunosuppressed rabbits (rabbits A, B, and C), depending on the extent of immunosuppression (see panel
F). Immunocompetent rabbits developed much smaller lesions (control), with tattoo marks indicating the sites of previous infection by week 12. (E) The
cyclosporine-dexamethasone immunosuppression regimen was found not to have a major effect on weight gain in juvenile (growing) rabbits during the time
course of the immunosuppression experiment. (F) To establish the extent of immunosuppression, T cell counts of the three immunosuppressed rabbits shown
in panel D are shown as gray columns (rabbits A, B, and C); T cell counts of a typical immunocompetent animal are shown as black columns.
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FIG 2 (A to D) Typical appearance of tattoo-marked tongue sites in two ROPV-infected rabbits at 4 weeks postinfection (A and C) and 12 weeks postinfection
(B and D). At 4 weeks postinfection (A and C), papillomas are apparent overlying tattoo-marked infection sites. At 12 weeks postinfection in the absence of
immunosuppression (B and D), only tattoo marks remain at previous sites of infection. (E) The appearance of tattoo marks in the uninfected control rabbit in
which no papilloma lesions developed during the course of the study are indistinguishable from the regressed sites shown in panels B and D. (F) Histology of a
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sion predisposed to autoinfection at new sites (Fig. 1B and C). A
repeat of this experiment confirmed our results, with papillomas
persisting beyond 12weeks postinfection in all three immunosup-
pressed rabbits but not in the control (Fig. 1D). The immunosup-
pressed rabbits maintained their appetite and continued to gain
body weight (Fig. 1E) but showed lower peripheral blood T cell
counts than those of control animals and those measured prior to
immunosuppression (Fig. 1F). In all instances, the size of the pap-
illomas appeared to correlate inversely with the total white blood
cell count, with the rabbit with the lowest white cell count devel-
oping the largest papillomas.
Immunosuppression leads to an elevation of the viral DNA
copy number at sites of previous disease. Having established a
schedule for drug-induced immunosuppression that was reason-
ably well tolerated and prevented papilloma regression in imma-
ture (growing) rabbits, we next went on to apply this procedure to
mature rabbits that had resolved the disease and had latent infec-
tions. Six rabbits were infected with ROPV prepared from rabbit
warts, with one rabbit undergoing a mock infection in which the
tongue was scarified but without the application of virions. At 4
weeks postinfection, rabbits were examined thoroughly under se-
dation to confirm that lesions had formed at all of the ROPV-
inoculated sites (Fig. 2A and C) but were absent from the mock-
infected control (Fig. 2E).When examined again at 8 and 12weeks
postinfection, papillomas were no longer visible in any of the in-
fected rabbits, indicating that immune-mediated spontaneous re-
gression had occurred (Fig. 2B and D). The absence of active in-
fection at 12 weeks postinfection was subsequently confirmed by
immunostaining with E4, MCM, and L1 antibodies on tongues
taken from culled animals as described previously (12). In keeping
with our previous rigorous analysis of600 regressed tissue slices,
we did not find evidence of active infection beyond papilloma
regression in immunocompetent animals, either at the level of
pathology or by immunofluorescence (12). To examine the effect
of immunosuppression postregression, we started four of the rab-
bits on immunosuppressive treatment at 12 weeks postinfection
with triweekly 15 mg/kg cyclosporine and biweekly 0.5 mg/kg
dexamethasone and kept two ROPV-infected rabbits as immuno-
competent controls. This immunosuppressive regimen was well
tolerated (Fig. 2G) and was continued for a further 12 weeks (i.e.,
until 24 weeks postinfection), after which time all of the rabbits
were culled. Examination of the rabbits under sedation at 16, 20,
and 24 weeks postinfection did not reveal the presence of visible
papillomas in the immunosuppressed animals, the immunocom-
petent ROPV-infected controls, or the uninfected rabbits. Immu-
nosuppressed animals showed a significant drop in total blood
lymphocytes, more specifically, in CD4 and CD8 cell numbers,
after 4 and 12 weeks of immunosuppression compared to the pre-
immunosuppression levels (Fig. 2H). Immunosuppressive treat-
ment was not continued beyond 12 weeks because of a general
appetite loss and a decline in body weight beyond 20% of the
starting weight. Tattoo-marked tongue infection sites were dis-
sected from culled animals, and ROPV DNA copy numbers were
determined relative to the glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) copy numbers by real-time PCR (12). From this
we established the ROPV genome copy number per cell as previ-
ously described. ROPVDNAcould not be detected in any of the 13
tattoo-marked mock-infected sites that were examined, even
though this rabbit was housed along with ROPV-infected animals
in a separate pen in the same room as the rest of the animals.
Among the animals that had been infected with ROPV, up to 26
tattoo-marked previous-disease sites were examined per rabbit,
with ROPV DNA being found at low levels in 23.1% (control 1 in
Fig. 2I) and 26.1% (control 2 in Fig. 2I) of these in the two immu-
nocompetent ROPV-infected control rabbits. These findings are
consistent with the formation of a latent infection, with ROPV
DNAbeing detectable at previously infected sites (12). In addition
to DNA, ROPV transcripts have also been reported in latent in-
fections (12). Transcript mapping was carried out initially to de-
termine the mRNA species present during productive infection
(Fig. 3A and B) and then to establish their levels (relative to
GAPDH) postregression. ThreemRNA species (i, iv, and vi in Fig.
3A and B) were identified that spanned the major E1ˆE4 splice
junction (nucleotides 11523ˆ540), with the levels of these ROPV
transcripts declining from approximately 1 copy/10 copies of
GAPDH mRNA to 1 copy/10,000 copies of GAPDH mRNA dur-
ing latency (Fig. 3C). Because of the diversity of expression ex-
pected as ROPV-infected cells undergo epithelial differentiation,
we cannot be certain where particular transcripts are produced
but assume (as with other papillomavirus infections) that species
v will predominate during productive infections. At latent sites,
transcripts capable of expressing E2 (species ii and iv)were present
at levels similar to those of transcripts that spanned the E1ˆE4
splice junction, with those encoding E6 and E7 (species i and ii)
being present at a lower abundance. This is reminiscent of what
has been reported previously in the CRPV system, where E1 and
E2 transcripts may contribute to genome maintenance, with E6
and E7 expression following UV irradiation (14). As we expected,
ROPV DNA (and RNA) was not identifiable at all previously in-
fected sites, either because of the low DNA copy number, the
imprecision of the tattoomarking system, or possibly also success-
ful disease clearance by the host immune system. In immunosup-
pressed rabbits, ROPV DNA was present at up to 100% of the
previously infected sites, and at sites where ROPV DNA could be
detected, the viral genomic copy number was typically 3- to 5-log-
fold higher in the immunosuppressed rabbits than in the immu-
nocompetent controls. All four of the immunosuppressed rabbits
contained at least one previously infected site that harbored
ROPV DNA at levels typically seen only in rabbits with an active
infection, despite there being no evidence of grossly visible papil-
lomas. This was not seen in the immunocompetent control ani-
mals either here or in our previous study (12). Overall, 19.6% of
single microlesion (with typical papilloma features) detected in rabbit 2 at 12 weeks postimmunosuppression. (G) In adult rabbits, the cyclosporine-dexameth-
asone immunosuppression regimen generally caused weight loss, with rabbits being culled when their weight loss exceeded 20% of their total body weight. The
graph shown is typical of what was seen in repeated experiments. (H) Decline in total lymphocyte counts (TLC; dark gray) and CD4- and CD8-positive (light
gray/white) lymphocyte levels following the onset of immunosuppression (IS) in the adult infected rabbits shown in panel I. (I) Numbers of ROPV copies per
copy of GAPDH DNA at sites of previous infection in postregression control rabbits (triangles) and postregression immunosuppressed rabbits (circles).
Cyclosporine-dexamethasone was administered at week 12 to the immunosuppressed animals, and viral copy numbers were measured at individual tattoo-
marked sites at week 24. ROPV/GAPDH copy numbers below the dotted line are those that are typically observed in rabbits with a latent infection or where no
ROPV is detectable (12). Elevated copy numbers were seen only at tattoo-marked sites in the immunosuppressed animals.
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the tattoo-marked sites taken from the immunosuppressed rab-
bits showed levels of ROPV DNA that were within the range typ-
ically seen during an active infection. Although the limited avail-
ability of tissue precluded an analysis of transcription patterns
upon immunosuppression, the available formalin-fixed residual
tissue permitted the sectioning of tissue from two tattoo-marked
infected sites in each of the four immunosuppressed rabbits. At
one of the sites examined in rabbit 2, amicroscopic papillomawas
found above a tattoo mark, suggesting that reactivation may, in
some instances, be manifested as microlesions (Fig. 2I and F).
ROPV persists in tongue tissue grafted onto immunodefi-
cient mice but does not undergo reactivation. The significant
problems with intolerance of rabbits to cyclosporine were insur-
mountable in our experiments, and we were unable to reliably
immunosuppress rabbits for longer than 12 weeks. Despite this
difficulty, we went on to repeat the infection and immunosup-
pression experiments by infecting a further cohort of nine rabbits
with ROPV and with induction of immunosuppression at 16
weeks postinfection in seven rabbits for a period of a further 16
weeks. In all infected rabbits, papillomas had formed and re-
gressed as expected by 12 weeks postinfection, and both immuno-
competent rabbits survived until the end of the experiment with
no adverse effect of signs of papilloma recurrence.Wewere unable
to sustain the immunosuppressed rabbits for the planned dura-
tion of the experiment, with all seven developing adverse clinical
symptoms as a consequence of cyclosporine and dexamethasone
administration (weight loss and severe abscess formation at injec-
tion sites and in the oral cavity) that necessitated culling on hu-
mane grounds. As a result, we were unable to examine the effects
of immunosuppression more extensively in this additional group
of animals. As an alternative, therefore, we decided to place in-
fected tissues into an environment devoid of T cell immunity by
grafting themunder the kidney capsules of immunodeficientmice
(20). By incubating rabbit tongue tissue with ROPV virions and
then grafting it into mice with severe combined immunodefi-
ciency (SCIDmice), we confirmed that the environment was sup-
portive of graft growth and survival, as well as allowing comple-
tion of the productive ROPV life cycle (Fig. 4). Tissues were then
taken from the tongues of previously infected rabbits culled at 12
to 16 weeks postinfection. Quantification of ROPV DNA in 34
tissue samples showed evidence of ROPV persistence at 19 sites.
Another 24 tissue samples were grafted into SCID mice for 16
weeks before being recovered for quantification of ROPV DNA,
and in all 24 samples, low levels of ROPVDNAwere found. Levels
of ROPVDNAwere lower than in ungrafted control tissues, which
was consistent with the persistence of a latent infection but not
with reactivation (Fig. 4C). The unexpected loss of ROPV ge-
nomes in the graft system may reflect the different growth pres-
FIG 3 (A) ROPV transcript map based on the analysis of cDNA prepared from a productive rabbit papilloma by a previously described methodology (26). The
positions of splice donor and acceptor sites were determined experimentally and are shown in red. Individual transcripts along with their coding capacities are
numbered i to vii at the bottom. The positions of the open reading frames and predicted promoter and polyadenylation sites have been reported previously (27)
and aremarked at the top. (B) Primers used for PCR amplification of ROPV cDNA fragments are indicated by red arrows, and the observed sizes of the amplified
products are shown in black. For each primer pair, the amplified bands used for sequence analysis are shown in the gel image to the right and are marked with
red asterisks. In addition to specific ROPV sequences, two additional bands were amplified in lanes 2 and 4 as a result of mispriming to cellular sequences. The
specific splice junctions present in each PCR fragment are shown on the left. The sequences of the primers used have been reported previously (12). (C) The
relative levels of transcripts containing the E1 ˆE4 splice junction (species i, v, and vi) were examined in productive papillomas (red column) and at sites of latent
infection (adjacent blue column). The E1 ˆE4 primer pair gave rise to a 129-bp fragment, as shown in track 1 in panel Bii. An approximately 4-log-fold difference
in levels was apparent. In latent infections, the relative level of transcripts spanning the E1 (species iii), E2 (species ii and iv), and E6 and E7 regions (species i and
ii) are shown to the right of the graph (blue columns) along with the identified transcripts that span these regions.
FIG 4 (A) Successful completion of the ROPV life cycle in infected tongue
epithelium grafted under the kidney capsules of SCID mice was confirmed by
immunostaining for the viral E4 protein (green) and by fluorescence in situ
hybridization to detect ROPV DNA (red). (B) Analysis of productively in-
fected tissue from SCIDmice revealed a characteristic papilloma pathology in
grafted epithelium. The images in panels A and B were captured with a 20
objective. (C) The characteristic pathology shown in panel B was absent from
latently infected tissue, even at 16weeks postgrafting. The ROPV copy number
per copy of GAPDH was higher before grafting (black column, ungrafted),
with the copy number declining by 16 weeks under the kidney capsule (gray
column, grafted), which is indicative of latent persistence but not reactivation.
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sures on latently infected cells (e.g., stem cells) in this system.
Although we anticipate that this immunodeficient environment
should be permissive for latent reactivation, we suspect that addi-
tional factors are necessary for this to occur that are not provided
in the kidney capsule system. Such factors include mechanical
irritation and stimulation of a “wound-healing” response, which
can influence the papillomavirus copy number in other model
systems and which can occur in an environment susceptible to
repeated irritation such as the tongue.
On the basis of our previous studies, we proposed a model of
papillomavirus latency in which viral gene expression is held in
check in the epithelial basal layer by constant immunosurveillance
and in which immunosuppressionmay be permissive of increased
virus activity, as suggested in humans (12, 21, 22). Our current
data support this hypothesis and show for the first time that sup-
pression of the adaptive immune system can lead directly to an
elevation of the viral DNA copy number at sites of previous infec-
tion, which is consistent with reactivation from latency. In our
experiments, however, it appears that additional reactivation
studies with rabbits will be difficult because of the problems in-
herent in the long-term administration of systemic immunosup-
pressive drugs to rabbits. A papillomavirus of the laboratory
mouse Mus musculus has recently been described, and although
MmuPV1 is likely to have distinct evolutionary adaptations that
reflect its position as a Pi papillomavirus, it is anticipated that this
model will be useful in further enhancing our understanding of
latent infections (23–25).
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